“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease.”
Pfizer CEO Albert Bourla on results of a Pfizer study on a third booster shot for the Pfizer-BioNTech COVID-19 vaccine.
nov 10, 2021
- Pfizer says their study of 10,000 individuals shows the third booster shot of their vaccine restores efficacy back to levels reached after their second shot (roughly 95%).
- Pfizer's COVID-19 vaccine is currently granted emergency use authorization for booster shots in the U.S. for those 65 and older, those 18 and older who are at high risk of severe COVID-19, or those working in high-risk environments. Now the company is seeking emergency use authorization for anyone 18 and older who has already received two doses of the vaccine.
- A new study from Israel shows waning immunity against COVID-19 amongst vaccine individuals in all age groups.
- Meanwhile, some doctors suggest even two doses of the vaccine aren't needed in individuals (and children) with prior infection. Pfizer had previously wanted the booster authorized for all age groups (ages 16+) who had full FDA approval for the initial series, but advisors had a concern about a rare inflammation of the heart muscle, especially in young men.
- Why It Matters: As Americans head into the holiday season, a concern still exists about gatherings and the potential impact of a possible rise in cases of COVID-19 - not only for families but for the economy at large.